Journal of Occupational
Health and Epidemiology
Rafsanjan university Of medical sciences
Volume 12, Issue 3 (Summer 2023)
J Occup Health Epidemiol 2023, 12(3): 132-138 |
Back to browse issues page
Ethics code: IR.SKUMS.REC.1399.198
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Badiei S, Rahmati S, Raeisi Shahraki H, Habibi Z. The Effect of Oral Silymarin on Remdesivir-Induced Hepatotoxicity and Clinical Course in Covid-19 Patients; A Double-Blind Randomized Controlled Trial. J Occup Health Epidemiol 2023; 12 (3) :132-138
URL: http://johe.rums.ac.ir/article-1-720-en.html
URL: http://johe.rums.ac.ir/article-1-720-en.html
Related article in
Google Scholar
Google Scholar
Similar articles
1- Resident in Internal Medicine, Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.
2- Ph.D. in Molecular Medicine, Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
3- Assistant Prof., Dept. of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4- Assistant Prof., Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran. ,Dr_z_habibi@yahoo.com
2- Ph.D. in Molecular Medicine, Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
3- Assistant Prof., Dept. of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4- Assistant Prof., Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran. ,
Article history
Received: 2023/03/11
Accepted: 2023/08/16
ePublished: 2023/09/28
Accepted: 2023/08/16
ePublished: 2023/09/28
Subject:
Epidemiology
Abstract: (696 Views)
Background: Remdesivir is a nucleoside inhibitor of RNA polymerase with the antiviral activity used in the treatment of COVID-19 pneumonia. One of the remdesivir side effects is hepatotoxicity. Given the growing body of data supporting silymarin's antiviral and hepatoprotective properties, the present research sought to explore the impact of silymarin on laboratory parameters, frequency of symptoms, and liver enzymes in COVID-19 patients.
Materials and Methods: In this double-blind randomized clinical trial 70 patients were divided into two groups of 35. Intervention group received remdesivir + 140 mg Silymarin, 3 times, daily for 1 week, and the control group received remdesivir + placebo. Patients' symptoms and laboratory findings were assessed at baseline and 5,7,10, and 14 days’ post enrollment.
Results: Liver enzymes level (aspartate aminotransferase, and alkaline phosphatase), and lactate dehydrogenase were significantly decreased in the intervention group (p < 0.05). Among the clinical symptoms, cough (p=0.03), shortness of breath (p= 0.006), headache (p=0.01), and muscle pain (p=0.03) were significantly lower in the treatment group comparing to the control group. Moreover, the severity of disease in the intervention group was substantially lower than that among the control group.
Conclusion: Concomitant use of remdesivir with silymarin might reduce hepatotoxicity and ultimately improve the patients' condition. More clinical trials with different dosages and larger sample sizes are recommended.
Materials and Methods: In this double-blind randomized clinical trial 70 patients were divided into two groups of 35. Intervention group received remdesivir + 140 mg Silymarin, 3 times, daily for 1 week, and the control group received remdesivir + placebo. Patients' symptoms and laboratory findings were assessed at baseline and 5,7,10, and 14 days’ post enrollment.
Results: Liver enzymes level (aspartate aminotransferase, and alkaline phosphatase), and lactate dehydrogenase were significantly decreased in the intervention group (p < 0.05). Among the clinical symptoms, cough (p=0.03), shortness of breath (p= 0.006), headache (p=0.01), and muscle pain (p=0.03) were significantly lower in the treatment group comparing to the control group. Moreover, the severity of disease in the intervention group was substantially lower than that among the control group.
Conclusion: Concomitant use of remdesivir with silymarin might reduce hepatotoxicity and ultimately improve the patients' condition. More clinical trials with different dosages and larger sample sizes are recommended.
References
1. Banitalebi S, Mohammadi K, Marjanian Z, Rabiei L, Masoudi R. The effect of COVID-19 epidemic on the mental health of nurses’ family members. J Educ Health Promot. 2021;10:368. [DOI] [PMID] [PMCID]
2. Rezakhani L, Kelishadrokhi AF, Soleimanizadeh A, Rahmati S. Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. Chem Phys Lipids. 2021;234:105009. [DOI] [PMID] [PMCID]
3. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. [DOI]
4. Chen LY, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, et al. Liver damage at admission is an independent prognostic factor for COVID‐19. J Dig Dis. 2020;21(9):512-8. [DOI] [PMID]
5. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337-42. [DOI] [PMID]
6. Gammeltoft KA, Zhou Y, Duarte Hernandez CR, Galli A, Offersgaard A, Costa R, et al. Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in Vitro. Antimicrob Agents Chemother. 2021;65(9):e0268020. [DOI] [PMID] [PMCID]
7. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63. [DOI] [PMID]
8. Silva CS, Portari GV, Vannucchi H. Antioxidant treatment and alcoholism. In: Patel VB, ed. Molecular Aspects of Alcohol and Nutrition. Cambridge, Massachusetts, United States: Academic Press; 2016. p.119-31. [DOI]
9. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12(6):559-67. [DOI] [PMID]
10. Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522-32. [DOI] [PMID] [PMCID]
11. Tao L, Qu X, Zhang Y, Song Y, Zhang SX. Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials. Can J Gastroenterol Hepatol. 2019;2019:3192351. [DOI] [PMID] [PMCID]
12. Asgarshirazi M, Shariat M, Sheikh M. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial. Hepatobiliary Pancreat Dis Int. 2017;16(3):296-302. [DOI] [PMID]
13. Ahmad MM, Rezk NA, Fawzy A, Sabry M. Protective effects of curcumin and silymarin against paracetamol induced hepatotoxicity in adult male albino rats. Gene. 2019;712:143966. [DOI] [PMID]
14. Heidarian E, Nouri A. Hepatoprotective effects of silymarin against diclofenac-induced liver toxicity in male rats based on biochemical parameters and histological study. Arch Physiol Biochem. 2021;127(2):112-8. [DOI] [PMID]
15. Osman EY, Abo-Elnasr SE, Zaher SM, AbuoHashish NA. The Natural Antioxidants Curcumin and Silymarin Afforded Hepatoprotective Effects against Deferasirox-Induced Hepatotoxicity. 2021. [DOI]
16. Abdel-Moneim AM, Al-Kahtani MA, El-Kersh MA, Al-Omair MA. Free radical-scavenging, anti-inflammatory/anti-fibrotic and hepatoprotective actions of taurine and silymarin against CCl4 induced rat liver damage. PLoS One. 2015;10(12):e0144509. [DOI] [PMID] [PMCID]
17. Hajizadeh Moghaddam A, Ahmadi Avendi E, Sayrafi R, Zare M. Comparison of the therapeutic effects of Silymarin and Nanosilymarin on hepatotoxicity induced by titanium dioxide nanoparticles. Avicenna J Clin Med. 2017;23(4):345-51. [DOI]
18. de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol. 2017;23(27):5004-17. [DOI] [PMID] [PMCID]
19. Rao PR, Viswanath RK. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Exp Clin Cardiol. 2007;12(4):179-87. [PMID] [PMCID]
20. Soltanian A, Mosallanejad B, Razi Jalali M, Najafzadeh Varzi H, Ghorbanpour M. Comparative evaluation of therapeutic effects of silymarin and hydrocortisone on clinical and hematological alterations, and organ injury (liver and heart) in a low-dose canine lipopolysaccharide-induced sepsis model. Vet Res Forum. 2020;11(3):235-41. [DOI] [PMID] [PMCID]
21. Bijak M, Saluk-Bijak J. Flavonolignans inhibit the arachidonic acid pathway in blood platelets. BMC Complement Altern Med. 2017;17(1):396. [DOI] [PMID] [PMCID]
22. Bouhalit S, Kechrid Z, Elfeki A. Effect of silymarin extracted from Silybum marianum on nickel hematotoxicity and nephrotoxicity in male albino wistar rats. Int J Pharm Pharm Sci. 2017;9(8):84-9. [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
